$XOS
Xos, Inc. Stock $xos

$xos Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000181949324000156 Filed on August 14, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$15.79M	$15.54M
YoY Change	-5.43%	226.78%
Cost Of Revenue	$12.93M	$13.51M
YoY Change	-12.13%	59.28%
Gross Profit	$2.864M	$2.030M
YoY Change	44.28%	-154.5%
Gross Profit Margin	18.14%	13.07%
Selling, General & Admin	$9.936M	$10.40M
YoY Change	-1.57%	-10.17%
% of Gross Profit	346.93%	512.32%
Research & Development	$2.619M	$2.998M
YoY Change	-42.01%	-42.13%
% of Gross Profit	91.45%	147.68%
Depreciation & Amortization	$800.0K	$900.0K
YoY Change	-57.89%	125.0%
% of Gross Profit	27.93%	44.33%
Operating Expenses	$12.56M	$13.40M
YoY Change	-14.07%	-20.05%
Operating Profit	-$9.691M	-$11.37M
YoY Change	-23.24%	-44.5%
Interest Expense	-$607.0K	-$372.0K
YoY Change	-56.33%	-87.97%
% of Operating Profit
Other Income/Expense, Net	-$710.0K	$1.545M
YoY Change	-58.86%	-138.99%
Pretax Income	-$10.51M	-$9.659M
YoY Change	-25.5%	-59.03%
Income Tax	$4.000K	$4.000K
% Of Pretax Income
Net Earnings	-$10.51M	-$9.663M
YoY Change	-25.48%	-59.02%
Net Earnings / Revenue	-66.57%	-62.2%
Basic Earnings Per Share	-$1.32	-$1.23
Diluted Earnings Per Share	-$1.32	-$1.23
COMMON SHARES
Basic Shares Outstanding	8.004M shares	7.873M shares
Diluted Shares Outstanding	7.984M shares	7.864M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.432M	$19.66M
YoY Change	-62.69%	-52.23%
Cash & Equivalents	$8.400M	$19.70M
Short-Term Investments
Other Short-Term Assets	$9.762M	$9.050M
YoY Change	30.16%	33.46%
Inventory	$42.40M	$41.36M
Prepaid Expenses
Receivables	$36.44M	$29.74M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$97.58M	$100.1M
YoY Change	6.67%	-9.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$16.24M	$17.17M
YoY Change	-22.29%	-22.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.694M	$6.145M
YoY Change	276.28%	284.3%
Total Long-Term Assets	$22.94M	$23.31M
YoY Change	1.0%	-1.74%
TOTAL ASSETS
Total Short-Term Assets	$97.58M	$100.1M
Total Long-Term Assets	$22.94M	$23.31M
Total Assets	$120.5M	$123.4M
YoY Change	5.54%	-8.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.920M	$3.097M
YoY Change	266.93%	33.26%
Accrued Expenses	$4.393M	$7.841M
YoY Change	-28.24%	5.45%
Deferred Revenue	$620.0K	$279.0K
YoY Change	-36.21%	-72.4%
Short-Term Debt	$2.087M	$1.341M
YoY Change	19.94%	-2.4%
Long-Term Debt Due	$21.44M	$1.945M
YoY Change	116.58%	-89.27%
Total Short-Term Liabilities	$50.19M	$20.05M
YoY Change	84.72%	-41.92%
LONG-TERM LIABILITIES
Long-Term Debt	$496.0K	$20.41M
YoY Change	-97.74%	-10.92%
Other Long-Term Liabilities	$18.94M	$23.77M
YoY Change	112.61%	139.52%
Total Long-Term Liabilities	$18.94M	$23.77M
YoY Change	112.61%	139.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$50.19M	$20.05M
Total Long-Term Liabilities	$18.94M	$23.77M
Total Liabilities	$69.67M	$64.21M
YoY Change	23.04%	-1.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$184.4M	-$173.9M
YoY Change	32.28%	38.78%
Common Stock	$1.000K	$1.000K
YoY Change	-94.44%	-94.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$50.84M	$59.22M
YoY Change
Total Liabilities & Shareholders Equity	$120.5M	$123.4M
YoY Change	5.54%	-8.22%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$10.51M	-$9.663M
YoY Change	-25.48%	-59.02%
Depreciation, Depletion And Amortization	$800.0K	$900.0K
YoY Change	-57.89%	125.0%
Cash From Operating Activities	-$11.52M	-$25.99M
YoY Change	33.61%	76.59%
INVESTING ACTIVITIES
Capital Expenditures	$148.0K	$126.0K
YoY Change	-177.89%	-88.56%
Acquisitions
YoY Change
Other Investing Activities	$125.0K	$0.00
YoY Change	-99.11%	-100.0%
Cash From Investing Activities	-$23.00K	-$126.0K
YoY Change	-100.16%	-100.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	40.00K	-484.0K
YoY Change	-100.4%	-93.77%
NET CHANGE
Cash From Operating Activities	-11.52M	-25.99M
Cash From Investing Activities	-23.00K	-126.0K
Cash From Financing Activities	40.00K	-484.0K
Net Change In Cash	-11.50M	-26.60M
YoY Change	158.43%	206.24%
FREE CASH FLOW
Cash From Operating Activities	-$11.52M	-$25.99M
Capital Expenditures	$148.0K	$126.0K
Free Cash Flow	-$11.67M	-$26.11M
YoY Change	38.37%	65.09%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	xos	Derivative Instrument Change In Amount Of Contingent Consideration Liability DerivativeInstrumentChangeInAmountOfContingentConsiderationLiability	-36000	usd
CY2023Q2	xos	Derivative Instrument Change In Amount Of Contingent Consideration Liability DerivativeInstrumentChangeInAmountOfContingentConsiderationLiability	-563000	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	60000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	62000	usd
CY2024Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1143000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27804000	usd
	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	945000	usd
CY2023Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1301000	usd
	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	743000	usd
CY2024Q2	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	324000	usd
CY2024Q2	us-gaap	Revenues Revenues	15535000	usd
CY2024Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	128000	usd
CY2023Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	307000	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	16953000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	16817000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	20050000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19573000	usd
CY2024Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	19944000	usd
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	19920000	usd
CY2024Q2	xos	Derivative Instrument Contingent Consideration Liability DerivativeInstrumentContingentConsiderationLiability	6000	usd
CY2023Q4	xos	Derivative Instrument Contingent Consideration Liability DerivativeInstrumentContingentConsiderationLiability	39000	usd
CY2024Q2	xos	Warrants And Rights Outstanding Noncurrent WarrantsAndRightsOutstandingNoncurrent	435000	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	23772000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8561000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	64207000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	48488000	usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7891000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7891000	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	233150000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	198456000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-173927000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-153261000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	59224000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	45196000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	93684000	usd
CY2024Q2	us-gaap	Revenues Revenues	15535000	usd
CY2023Q2	us-gaap	Revenues Revenues	4754000	usd
CY2023Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0333
CY2023Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0333
CY2023Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0333
CY2023Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0333
CY2023Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0333
CY2023Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0333
CY2023Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0333
CY2023Q4	xos	Warrants And Rights Outstanding Noncurrent WarrantsAndRightsOutstandingNoncurrent	395000	usd
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	123431000	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	13505000	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	8479000	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	2030000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	-3725000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9176000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9816000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2998000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5181000	usd
CY2024Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1224000	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1761000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	13398000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	16758000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-11368000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-20483000	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1545000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3963000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9659000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23576000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-9663000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-23578000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax	0	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax	0	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	0	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	281000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9663000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23297000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.23
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.14
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.23
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.14
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7864000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5700000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7864000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5700000	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	112075000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1987000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	382000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23929000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	89751000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2037000	usd
CY2023Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	374000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	212000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	924000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23297000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	69260000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	45196000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1968000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	31856000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	47000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11003000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	67806000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1634000	usd
CY2024Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	563000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9663000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	59224000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-20666000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-47909000	usd
	us-gaap	Depreciation Depreciation	1780000	usd
	us-gaap	Depreciation Depreciation	1389000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	814000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	771000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	24000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4330000	usd
	xos	Amortization Of Insurance Premiums AmortizationOfInsurancePremiums	1433000	usd
	xos	Amortization Of Insurance Premiums AmortizationOfInsurancePremiums	2390000	usd
	xos	Inventory Reserve Increase Decrease InventoryReserveIncreaseDecrease	-1236000	usd
	xos	Inventory Reserve Increase Decrease InventoryReserveIncreaseDecrease	-58000	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	1543000	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-40000	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	210000	usd
	xos	Derivative Instrument Change In Amount Of Contingent Consideration Liability DerivativeInstrumentChangeInAmountOfContingentConsiderationLiability	-33000	usd
	xos	Derivative Instrument Change In Amount Of Contingent Consideration Liability DerivativeInstrumentChangeInAmountOfContingentConsiderationLiability	-511000	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-91000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3640000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4066000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-572000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	371000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	14628000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2015000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2353000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2130000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1655000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-930000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2071000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-428000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-616000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-5809000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-22000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-40576000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30042000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	156000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1354000	usd
	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	0	usd
	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	497000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	37465000	usd
	xos	Cash Acquired From Asset Acquisition CashAcquiredFromAssetAcquisition	51355000	usd
	xos	Cash Acquired From Asset Acquisition CashAcquiredFromAssetAcquisition	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	51199000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	36608000	usd
	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	1150000	usd
	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	1205000	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	1785000	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	2187000	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1448000	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	2877000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	14969000	usd
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	usd
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	748000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	821000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	756000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	47000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	924000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1577000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-17437000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9046000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10871000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11640000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38675000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20686000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27804000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19656000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27804000	usd
CY2024Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	1030000	usd
CY2023Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20686000	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	1261000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	16000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	xos	Increase Decrease In Capital Expenditures Accrual IncreaseDecreaseInCapitalExpendituresAccrual	-35000	usd
	xos	Increase Decrease In Capital Expenditures Accrual IncreaseDecreaseInCapitalExpendituresAccrual	44000	usd
	xos	Conversion Of Interest Payable On Convertible Debentures ConversionOfInterestPayableOnConvertibleDebentures	0	usd
	xos	Conversion Of Interest Payable On Convertible Debentures ConversionOfInterestPayableOnConvertibleDebentures	12000	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	200000	usd
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	54630000	usd
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0	usd
	us-gaap	Stock Issued1 StockIssued1	31856000	usd
	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19700000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-40600000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30000000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39300000	usd
CY2022Q3	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	20000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the balance sheet date, as well as reported amounts of revenues and expenses during the reporting periods. The areas with significant estimates and judgments include, among others, inventory valuation, incremental borrowing rates for assessing operating and financing lease liabilities, useful lives of property and equipment, stock-based compensation, product warranty liability, and valuation of convertible debt and related embedded derivatives, common stock warrant liability, earn-out shares liability and valuations utilized in connection with acquisitions. Management bases its estimates on historical experience and on various other assumptions believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates, and such differences could be material to the Company’s financial statements.</span></div>
CY2024Q2	us-gaap	Receivable For Recovery Of Import Duties Net ReceivableForRecoveryOfImportDutiesNet	2700000	usd
CY2024Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1199000	usd
CY2023Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1155000	usd
CY2023Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1306000	usd
CY2022Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1099000	usd
CY2024Q2	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	400000	usd
CY2023Q2	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	527000	usd
	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	922000	usd
CY2024Q2	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	344000	usd
CY2023Q2	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	673000	usd
	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	759000	usd
CY2024Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1143000	usd
CY2023Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1301000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit and Business Risk</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. As of June 30, 2024 and 2023, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</span></div>
	xos	Defined Contribution Plan Auto Enrollment Contributions Per Employee Percent DefinedContributionPlanAutoEnrollmentContributionsPerEmployeePercent	0.03
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	0	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	0	usd
CY2024Q2	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	0	usd
CY2023Q2	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	0	usd
CY2023Q2	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	117000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	851000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	381000	usd
CY2023Q2	us-gaap	Revenues Revenues	4754000	usd
	us-gaap	Revenues Revenues	28697000	usd
	us-gaap	Revenues Revenues	9451000	usd
CY2024Q2	us-gaap	Severance Costs1 SeveranceCosts1	0	usd
	us-gaap	Severance Costs1 SeveranceCosts1	2000000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	41400000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	37800000	usd
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	33019000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	30357000	usd
CY2024Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	5828000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	3033000	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2509000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4453000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	41356000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	37843000	usd
CY2024Q2	xos	Prepaid Inventory PrepaidInventory	2801000	usd
CY2023Q4	xos	Prepaid Inventory PrepaidInventory	1745000	usd
CY2024Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	3417000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2796000	usd
CY2024Q2	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	315000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	811000	usd
CY2024Q2	us-gaap	Prepaid Insurance PrepaidInsurance	1394000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1310000	usd
CY2024Q2	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	408000	usd
CY2023Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	408000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8335000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7070000	usd
CY2024Q2	us-gaap	Security Deposit SecurityDeposit	2661000	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	1599000	usd
CY2024Q2	us-gaap	Receivable For Recovery Of Import Duties Net ReceivableForRecoveryOfImportDutiesNet	2709000	usd
CY2023Q4	us-gaap	Receivable For Recovery Of Import Duties Net ReceivableForRecoveryOfImportDutiesNet	0	usd
CY2024Q2	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	775000	usd
CY2023Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	739000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6145000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2338000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7841000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7435000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	279000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	690000	usd
CY2024Q2	xos	Deposits Of Customers Current DepositsOfCustomersCurrent	1099000	usd
CY2023Q4	xos	Deposits Of Customers Current DepositsOfCustomersCurrent	2364000	usd
CY2024Q2	us-gaap	Standard Product Warranty Accrual Current StandardProductWarrantyAccrualCurrent	1143000	usd
CY2023Q4	us-gaap	Standard Product Warranty Accrual Current StandardProductWarrantyAccrualCurrent	1306000	usd
CY2024Q2	us-gaap	Notes Payable NotesPayable	363000	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	350000	usd
CY2024Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	1341000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	1003000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2942000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1664000	usd
CY2024Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1945000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2005000	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	16953000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	16817000	usd
	xos	Contract With Customer Liability Revenue Recognized Including Opening Balance ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance	600000	usd
	xos	Contract With Customer Liability Revenue Recognized Including Opening Balance ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance	400000	usd
CY2023	xos	Contract With Customer Liability Revenue Recognized Including Opening Balance ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance	400000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	4466000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	2985000	usd
CY2024Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	497000	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	593000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18345000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3511000	usd
CY2024Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	464000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1472000	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	23772000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8561000	usd
CY2021Q3	xos	Derivative Instrument Contingent Consideration Liability Shares DerivativeInstrumentContingentConsiderationLiabilityShares	540000	shares
CY2024Q2	xos	Derivative Instrument Contingent Consideration Liability DerivativeInstrumentContingentConsiderationLiability	6000	usd
CY2023Q4	xos	Derivative Instrument Contingent Consideration Liability DerivativeInstrumentContingentConsiderationLiability	39000	usd
	xos	Derivative Instrument Gain Loss Change In Amount Of Contingent Consideration Liability DerivativeInstrumentGainLossChangeInAmountOfContingentConsiderationLiability	33000	usd
	xos	Derivative Instrument Gain Loss Change In Amount Of Contingent Consideration Liability DerivativeInstrumentGainLossChangeInAmountOfContingentConsiderationLiability	500000	usd
CY2024Q2	xos	Derivative Instrument Gain Loss Change In Amount Of Contingent Consideration Liability DerivativeInstrumentGainLossChangeInAmountOfContingentConsiderationLiability	36000	usd
CY2023Q2	xos	Derivative Instrument Gain Loss Change In Amount Of Contingent Consideration Liability DerivativeInstrumentGainLossChangeInAmountOfContingentConsiderationLiability	600000	usd
CY2024Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	usd
CY2022Q3	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	20000000	usd
CY2022Q3	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	20000000	usd
CY2024Q2	xos	Capital Stock Shares Authorized CapitalStockSharesAuthorized	1010000000	shares
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	xos	Common Stock Voting Rights Number Of Votes CommonStockVotingRightsNumberOfVotes	1	vote
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q2	xos	Debt Instrument Redemption Prepayment Reduction Period Prior To Prepayment Date DebtInstrumentRedemptionPrepaymentReductionPeriodPriorToPrepaymentDate	P30D
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	5500	shares
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	99566	shares
	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	46750	usd
	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	924179	usd
CY2024Q2	xos	Sale Of Stock Remaining Commitment Amount Available SaleOfStockRemainingCommitmentAmountAvailable	119400000	usd
CY2023Q4	xos	Sale Of Stock Remaining Commitment Amount Available SaleOfStockRemainingCommitmentAmountAvailable	119500000	usd
	xos	Class Of Warrant Or Right Fair Market Value Threshold Consecutive Trading Days Ending On Third Trading Day Prior To Notice Of Redemption ClassOfWarrantOrRightFairMarketValueThresholdConsecutiveTradingDaysEndingOnThirdTradingDayPriorToNoticeOfRedemption	P10D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	22512	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.40
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.51
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y6M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	168194	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	20659	shares
CY2024Q1	xos	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue	0.38
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.50
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	141076	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1853	shares
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.56
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.63
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y9M14D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	17806	usd
CY2024Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	16	shares
CY2024Q2	xos	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue	0.64
CY2024Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.46
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	115	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1837	shares
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.56
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.63
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y6M14D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	11532	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1765	shares
CY2024Q2	xos	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageGrantDateFairValue	0.55
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.64
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y6M3D
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	11071	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	115	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	179000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	141000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	180000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1600000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3600000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2100000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4100000	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1634000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2054000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3640000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4066000	usd
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	6600000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M17D
CY2024Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	22924000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	22662000	usd
CY2024Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	9936000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	8002000	usd
CY2024Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	12988000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	14660000	usd
CY2024Q2	us-gaap	Depreciation Depreciation	900000	usd
CY2023Q2	us-gaap	Depreciation Depreciation	400000	usd
	us-gaap	Depreciation Depreciation	1800000	usd
	us-gaap	Depreciation Depreciation	1400000	usd
CY2024Q2	xos	Unrecorded Unconditional Purchase Obligation Number Of Vendors UnrecordedUnconditionalPurchaseObligationNumberOfVendors	2	vendor
CY2024Q2	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	400000	usd
CY2024Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0004
CY2023Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0001
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0004
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0001
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-9663000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-23578000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-20666000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-47909000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9663000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23578000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20666000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-47909000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-9663000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-23578000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-20666000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-47909000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7864000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5700000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6986000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5667000	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.23
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.14
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.96
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.45
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7864000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5700000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6986000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5667000	shares
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.23
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.14
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.96
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.45
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001819493-24-000156-index-headers.html	Edgar Link	pending
0001819493-24-000156-index.html	Edgar Link	pending
0001819493-24-000156.txt	Edgar Link	pending
0001819493-24-000156-xbrl.zip	Edgar Link	pending
ex-311xceosec302certificat.htm	Edgar Link	pending
ex-312xcfosec302certificat.htm	Edgar Link	pending
ex-321xceocfosec906certifi.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
xos-20240630.htm	Edgar Link	pending
xos-20240630.xsd	Edgar Link	pending
xos-20240630_g1.jpg	Edgar Link	pending
xos-20240630_cal.xml	Edgar Link	unprocessable
xos-20240630_def.xml	Edgar Link	unprocessable
xos-20240630_lab.xml	Edgar Link	unprocessable
xos-20240630_pre.xml	Edgar Link	unprocessable
xos-20240630_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$XOS
Xos, Inc. Stock $xos

2024 Q3 Form 10-Q Financial Statement

#000181949324000156 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XOS Xos, Inc. Stock $xos

2024 Q3 Form 10-Q Financial Statement

#000181949324000156 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XOS
Xos, Inc. Stock $xos